The Current State of the Art in PARP Inhibitor-Based Delivery Nanosystems

Poly (adenosine diphosphate [ADP]–ribose) polymerases inhibitors (PARPi), the first clinically approved drug that exhibits synthetic lethality, are moving to the forefront of cancer treatments. Currently, the oral bioavailability of PARPi is quite low; thus, it is a major challenge to effectively an...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Lisha, Xu, Xiaoling, Chen, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413625/
https://www.ncbi.nlm.nih.gov/pubmed/36015275
http://dx.doi.org/10.3390/pharmaceutics14081647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413625/
https://www.ncbi.nlm.nih.gov/pubmed/36015275
http://dx.doi.org/10.3390/pharmaceutics14081647

Ejemplares similares